Group 1 CD1 in Infectious Disease and T Cell Development
Group 1 CD1 in Infectious Disease and T Cell Development
批准号:
7994164
负责人:
Chyung-Ru Wang
金额:
$37.74万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-12-01 至 2014-11-30
关键词:
AddressAdoptive Cell TransfersAdoptive TransferAnimal ModelAntigen-Presenting CellsAntigensBacterial InfectionsCD1 AntigensCause of DeathCell LineCell WallCell physiologyCellsCommunicable DiseasesCytotoxic T-LymphocytesDataDendritic CellsDevelopmentDiseaseDrug or chemical Tissue DistributionEpitopesExhibitsExposure toFamilyFrequenciesHumanImmune responseImmunityImmunizationIndividualInfectionKineticsLeadLipidsLocationMeasuresMediatingModelingMusMycobacterium InfectionsMycobacterium tuberculosisMycobacterium tuberculosis antigensMycolic AcidNatural ImmunityNaturePatternPhenotypePlayProductionPropertyProtocols documentationRegulationRelative (related person)ResistanceRoleSecondary ImmunizationStudy modelsSubunit VaccinesSurfaceT cell responseT-Cell DevelopmentT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTestingTransgenic MiceTransgenic ModelTransgenic OrganismsTuberculosisTuberculosis VaccinesVaccinesadaptive immunityautoreactive T cellautoreactivitybasecytokineefficacy testingenzyme linked immunospot assayimmune resistanceimmunogenicityimprovedin vivomouse modelmycobacterialnovelnovel vaccinesoutcome forecastprotective efficacypublic health relevanceresponsevaccination against tuberculosisvaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The human group 1 CD1 molecules CD1a, CD1b, and CD1c have been shown to present both endogenous and mycobacterial-derived lipid antigens to various subsets of T cells. Group 1 CD1- restricted immune responses have been implicated in anti-mycobacterial immunity; however, their role in infection is unknown due to the lack of a suitable animal model. We have generated transgenic mice (hCD1Tg) that express human group 1 CD1 molecules in a pattern similar to humans, and support the development of T cells that are restricted to group 1 CD1. Both infection with Mycobacterium tuberculosis (Mtb) and immunization with Mtb lipids elicit group 1 CD1-restricted Mtb- lipid antigen-specific T cell responses in hCD1Tg mice, and secondary immunization induces more rapid responses than primary immunization. In addition, group 1 CD1-restricted T cells generated from hCD1Tg mice can recognize mycobacterial antigens described in humans. Taken together, these data indicate that group 1 CD1-restricted T cells play a role in adaptive immunity and could serve as targets for Mtb vaccine development. This proposal seeks to study the in vivo function of group 1 CD1-restricted T cells during Mtb infection and to test the efficacy of a lipid-based vaccine for Mtb that targets group 1 CD1-restricted T cells using the hCD1Tg mouse model. In Aim 1, we propose to identify immunodominant Mtb antigens presented by group 1 CD1 in Mtb-infected hCD1Tg mice and evaluate the protective efficacy of these antigens in a lipid vaccine upon Mtb challenge. In Aim 2, we propose to generate retrogenic mice which express TCRs specific to distinct Mtb lipid antigens, and investigate the activation kinetics, effector function, and protective role of these T cells using an adoptive transfer approach. While group 1 CD1-restricted Mtb lipid antigen-specific T cells recognize foreign antigens directly, group 1 CD1-restricted autoreactive T cells may be activated during infection through recognition of endogenous antigen presented by TLR-matured antigen presenting cells and contribute to innate anti-mycobacterial responses, analogous to what has been described for group 2 CD1d-restricted NKT cells. In our third Aim, we will therefore investigate the developmental requirements and function of autoreactive group 1 CD1-restricted T cells during Mtb infection using a TCR transgenic model. Collectively, these studies will lead to a better understanding of how group 1 CD1-restricted T cells contribute to protective immunity against Mtb and whether they can be targeted for the development of lipid antigen-based Mtb vaccines.
PUBLIC HEALTH RELEVANCE: Tuberculosis (TB) remains the leading cause of death due to bacterial infection. In spite of this, an effective vaccine against Mycobacterium tuberculosis (Mtb), the causative agent of TB, is lacking. Studies in humans have shown that various lipid components of the mycobacterial cell wall can be recognized by group 1 CD1-restricted T cells, however, the contribution of these T cells to immunity against Mtb is poorly understood. This study proposes to utilize novel animal models both to characterize the immune responses mediated by group 1 CD1-restricted T cells during Mtb infection, and to test the ability of lipid vaccines to confer resistance to Mtb infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A new mouse model to study the function of CD1b-restricted germline encoded, mycolyl lipid-reactive (GEM) T cells
-
批准号:10727275
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2023
-
负责人:Chyung-Ru Wang
-
依托单位:
The regulation and functions of Group 1 CD1-restricted T cells
-
批准号:10779737
-
项目类别:
-
资助金额:$66.57万
-
财政年份:2023
-
负责人:Chyung-Ru Wang
-
依托单位:
The role of non-classical MHC class I molecules in immune responses to Mycobacterium tuberculosis infection
-
批准号:10402266
-
项目类别:
-
资助金额:$56.74万
-
财政年份:2018
-
负责人:Chyung-Ru Wang
-
依托单位:
The role of non-classical MHC class I molecules in immune responses to Mycobacterium tuberculosis infection
-
批准号:9918253
-
项目类别:
-
资助金额:$61.75万
-
财政年份:2018
-
负责人:Chyung-Ru Wang
-
依托单位:
Development of Lipid-based Nanoparticle Vaccines Against Mycobacterium tuberculosis
-
批准号:9298853
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2017
-
负责人:Chyung-Ru Wang
-
依托单位:
The Role of Group 1 CD1-Restricted T Cells in Atherosclerosis
-
批准号:8603279
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2013
-
负责人:Chyung-Ru Wang
-
依托单位:
The Role of Group 1 CD1-Restricted T Cells in Atherosclerosis
-
批准号:8451723
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2013
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:6828264
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:7152581
-
项目类别:
-
资助金额:$33.4万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:7650923
-
项目类别:
-
资助金额:$27.73万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:6705265
-
项目类别:
-
资助金额:$36.83万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:6985396
-
项目类别:
-
资助金额:$33.39万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
The Role of Group 1 CD1-restricted T Cells in Infectious Disease
-
批准号:9207061
-
项目类别:
-
资助金额:$45.77万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:8580547
-
项目类别:
-
资助金额:$37.74万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:7791707
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:8389840
-
项目类别:
-
资助金额:$35.48万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:7320282
-
项目类别:
-
资助金额:$5.74万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
The Role of Group 1 CD1-restricted T Cells in Infectious Disease
-
批准号:9106043
-
项目类别:
-
资助金额:$25.16万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
The Role of Group 1 CD1-restricted T Cells in Infectious Disease
-
批准号:9104332
-
项目类别:
-
资助金额:$44.87万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位:
Group 1 CD1 in Infectious Disease and T Cell Development
-
批准号:8197215
-
项目类别:
-
资助金额:$37.74万
-
财政年份:2003
-
负责人:Chyung-Ru Wang
-
依托单位: